CONCLUSION
RA, T2DM
The EMPT‐ANGINA trial showed that in people with concurrent T2DM and RA, adding empagliflozin to regular anti‐hyperglycemic treatments was linked to a significant decrease in angina symptoms and an increase in exercise capacity compared to placebo. These findings justify the use of empagliflozin in patients with DM and RA for clinical cardiologists.